JOQORA

Joqora is a Danish biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). A spin-out from the University of Copenhagen and an alumnus of the BioInnovation Institute (BII), the company leverages deep expertise in structural biology and computational chemistry to address orphan and difficult-to-drug GPCRs. Their primary focus is on developing highly selective modulators for central nervous system (CNS) disorders, with a lead program targeting GPR139 for the treatment of schizophrenia. Joqora's approach aims to provide more effective treatments with fewer side effects by precisely modulating receptor signaling pathways.